APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Malignant Mesothelioma Drugs

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Malignant Mesothelioma Drugs Industry Growth and Trends Forecast to 2032

Report ID 174010050120 December 2025121 pages

Choose your research edition.

Industry ResearchMalignant Mesothelioma Drugs Industry Research Report 2026150 pages · $2,950 USDIndustry Growth & TrendsGlobal Malignant Mesothelioma Drugs Industry Growth and Trends Forecast to 2032121 pages · $3,450 USDMarket StructureGlobal Malignant Mesothelioma Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Malignant Mesothelioma Drugs Market Outlook and Growth Opportunities 2026204 pages · $4,250 USDMarket Analysis & ForecastGlobal Malignant Mesothelioma Drugs Market Analysis and Forecast 2026-2032200 pages · $4,950 USD

Market perspective

The global Malignant Mesothelioma Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Malignant Mesothelioma Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Malignant Mesothelioma Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Malignant Mesothelioma Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Malignant Mesothelioma Drugs include Teva Pharmaceuticals, Sun Pharmaceuticals, Sanofi, Novartis, Merck, Mylan, Roche, Eli Lilly and Pfizer, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Malignant Mesothelioma Drugs market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Malignant Mesothelioma Drugs market size, estimates, and forecasts are presented in terms of sales volume (K Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Malignant Mesothelioma Drugs market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Malignant Mesothelioma Drugs.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Malignant Mesothelioma Drugs market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Malignant Mesothelioma Drugs Market by Company

Teva Pharmaceuticals

Sun Pharmaceuticals

Sanofi

Novartis

Merck

Mylan

Roche

Eli Lilly

Pfizer

Fresenius Kabi

AstraZeneca

Polaris Pharmaceuticals

Ono Pharmaceutical

Nichi-Iko Pharmaceutical

MolMed

Kyowa Hakko Kirin

Corden Pharma

Concordia International

Bristol-Myers Squibb

Boehringer Ingelheim GmbH

Malignant Mesothelioma Drugs Segment by Type

Vinorelbine

Cisplatin

Pemetrexed

Carboplatin

Gemcitabine

Others

Malignant Mesothelioma Drugs Segment by Application

Retail Pharmacies

Hospital Pharmacies

Oncology Centers

Others

Malignant Mesothelioma Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Malignant Mesothelioma Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Malignant Mesothelioma Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Malignant Mesothelioma Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Malignant Mesothelioma Drugs manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Malignant Mesothelioma Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Vinorelbine Table 2. Major Company of Cisplatin Table 3. Major Company of Pemetrexed Table 4. Major Company of Carboplatin Table 5. Major Company of Gemcitabine Table 6. Major Company of Others Table 7. Global Malignant Mesothelioma Drugs Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 8. Global Malignant Mesothelioma Drugs Sales by Type (2021-2026) & (K Units) Table 9. Global Malignant Mesothelioma Drugs Sales Market Share in Volume by Type (2021-2026) Table 10. Global Malignant Mesothelioma Drugs Sales by Type (2021-2026) & (US$ Million) Table 11. Global Malignant Mesothelioma Drugs Sales Market Share in Value by Type (2021-2026) Table 12. Global Malignant Mesothelioma Drugs Price by Type (2021-2026) & (US$/Unit) Table 13. Global Malignant Mesothelioma Drugs Sales by Type (2027-2032) & (K Units) Table 14. Global Malignant Mesothelioma Drugs Sales Market Share in Volume by Type (2027-2032) Table 15. Global Malignant Mesothelioma Drugs Sales by Type (2027-2032) & (US$ Million) Table 16. Global Malignant Mesothelioma Drugs Sales Market Share in Value by Type (2027-2032) Table 17. Global Malignant Mesothelioma Drugs Price by Type (2027-2032) & (US$/Unit) Table 18. North America Malignant Mesothelioma Drugs Sales by Type (2021-2026) & (K Units) Table 19. North America Malignant Mesothelioma Drugs Sales by Type (2021-2026) & (US$ Million) Table 20. Europe Malignant Mesothelioma Drugs Sales by Type (2021-2026) & (K Units) Table 21. Europe Malignant Mesothelioma Drugs Sales by Type (2021-2026) & (US$ Million) Table 22. Asia-Pacific Malignant Mesothelioma Drugs Sales by Type (2021-2026) & (K Units) Table 23. Asia-Pacific Malignant Mesothelioma Drugs Sales by Type (2021-2026) & (US$ Million) Table 24. Latin America Malignant Mesothelioma Drugs Sales by Type (2021-2026) & (K Units) Table 25. Latin America Malignant Mesothelioma Drugs Sales by Type (2021-2026) & (US$ Million) Table 26. Middle East and Africa Malignant Mesothelioma Drugs Sales by Type (2021-2026) & (K Units) Table 27. Middle East and Africa Malignant Mesothelioma Drugs Sales by Type (2021-2026) & (US$ Million) Table 28. Malignant Mesothelioma Drugs Industry Trends Table 29. Malignant Mesothelioma Drugs Industry Drivers Table 30. Malignant Mesothelioma Drugs Industry Opportunities and Challenges Table 31. Malignant Mesothelioma Drugs Industry Restraints Table 32. Global Malignant Mesothelioma Drugs Sales Revenue by Company (US$ Million) & (2021-2026) Table 33. Global Malignant Mesothelioma Drugs Revenue Market Share by Company (2021-2026) Table 34. Global Malignant Mesothelioma Drugs Sales by Company (2021-2026) & (K Units) Table 35. Global Malignant Mesothelioma Drugs Sales Share by Company (2021-2026) Table 36. Global Malignant Mesothelioma Drugs Market Price by Company (2021-2026) & (US$/Unit) Table 37. Global Malignant Mesothelioma Drugs Industry Company Ranking, 2024 VS 2025 VS 2026 Table 38. Global Malignant Mesothelioma Drugs Major Company Production Sites and Headquarters Table 39. Global Malignant Mesothelioma Drugs Company, Product Type & Application Table 40. Global Malignant Mesothelioma Drugs Company Establishment Date Table 41. Global Company Market Concentration Ratio (CR5 and HHI) Table 42. Global Malignant Mesothelioma Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 43. Global Malignant Mesothelioma Drugs Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 44. Global Malignant Mesothelioma Drugs Sales by Region (2021-2026) & (K Units) Table 45. Global Malignant Mesothelioma Drugs Sales Market Share in Volume by Region (2021-2026) Table 46. Global Malignant Mesothelioma Drugs Sales by Region (2021-2026) & (US$ Million) Table 47. Global Malignant Mesothelioma Drugs Sales Market Share in Value by Region (2021-2026) Table 48. Global Malignant Mesothelioma Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 49. Global Malignant Mesothelioma Drugs Sales by Region (2027-2032) & (K Units) Table 50. Global Malignant Mesothelioma Drugs Sales Market Share in Volume by Region (2027-2032) Table 51. Global Malignant Mesothelioma Drugs Sales by Region (2027-2032) & (US$ Million) Table 52. Global Malignant Mesothelioma Drugs Sales Market Share in Value by Region (2027-2032) Table 53. Global Malignant Mesothelioma Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 54. Global Malignant Mesothelioma Drugs Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 55. Global Malignant Mesothelioma Drugs Sales by Application (2021-2026) & (K Units) Table 56. Global Malignant Mesothelioma Drugs Sales Market Share in Volume by Application (2021-2026) Table 57. Global Malignant Mesothelioma Drugs Sales by Application (2021-2026) & (US$ Million) Table 58. Global Malignant Mesothelioma Drugs Sales Market Share in Value by Application (2021-2026) Table 59. Global Malignant Mesothelioma Drugs Price by Application (2021-2026) & (US$/Unit) Table 60. Global Malignant Mesothelioma Drugs Sales by Application (2027-2032) & (K Units) Table 61. Global Malignant Mesothelioma Drugs Sales Market Share in Volume by Application (2027-2032) Table 62. Global Malignant Mesothelioma Drugs Sales by Application (2027-2032) & (US$ Million) Table 63. Global Malignant Mesothelioma Drugs Sales Market Share in Value by Application (2027-2032) Table 64. Global Malignant Mesothelioma Drugs Price by Application (2027-2032) & (US$/Unit) Table 65. North America Malignant Mesothelioma Drugs Sales by Application (2021-2026) & (K Units) Table 66. North America Malignant Mesothelioma Drugs Sales by Application (2021-2026) & (US$ Million) Table 67. Europe Malignant Mesothelioma Drugs Sales by Application (2021-2026) & (K Units) Table 68. Europe Malignant Mesothelioma Drugs Sales by Application (2021-2026) & (US$ Million) Table 69. Asia-Pacific Malignant Mesothelioma Drugs Sales by Application (2021-2026) & (K Units) Table 70. Asia-Pacific Malignant Mesothelioma Drugs Sales by Application (2021-2026) & (US$ Million) Table 71. Latin America Malignant Mesothelioma Drugs Sales by Application (2021-2026) & (K Units) Table 72. Latin America Malignant Mesothelioma Drugs Sales by Application (2021-2026) & (US$ Million) Table 73. Middle East and Africa Malignant Mesothelioma Drugs Sales by Application (2021-2026) & (K Units) Table 74. Middle East and Africa Malignant Mesothelioma Drugs Sales by Application (2021-2026) & (US$ Million) Table 75. Teva Pharmaceuticals Company Information Table 76. Teva Pharmaceuticals Business Overview Table 77. Teva Pharmaceuticals Malignant Mesothelioma Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 78. Teva Pharmaceuticals Malignant Mesothelioma Drugs Product Portfolio Table 79. Teva Pharmaceuticals Recent Development Table 80. Sun Pharmaceuticals Company Information Table 81. Sun Pharmaceuticals Business Overview Table 82. Sun Pharmaceuticals Malignant Mesothelioma Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 83. Sun Pharmaceuticals Malignant Mesothelioma Drugs Product Portfolio Table 84. Sun Pharmaceuticals Recent Development Table 85. Sanofi Company Information Table 86. Sanofi Business Overview Table 87. Sanofi Malignant Mesothelioma Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 88. Sanofi Malignant Mesothelioma Drugs Product Portfolio Table 89. Sanofi Recent Development Table 90. Novartis Company Information Table 91. Novartis Business Overview Table 92. Novartis Malignant Mesothelioma Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. Novartis Malignant Mesothelioma Drugs Product Portfolio Table 94. Novartis Recent Development Table 95. Merck Company Information Table 96. Merck Business Overview Table 97. Merck Malignant Mesothelioma Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. Merck Malignant Mesothelioma Drugs Product Portfolio Table 99. Merck Recent Development Table 100. Mylan Company Information Table 101. Mylan Business Overview Table 102. Mylan Malignant Mesothelioma Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 103. Mylan Malignant Mesothelioma Drugs Product Portfolio Table 104. Mylan Recent Development Table 105. Roche Company Information Table 106. Roche Business Overview Table 107. Roche Malignant Mesothelioma Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 108. Roche Malignant Mesothelioma Drugs Product Portfolio Table 109. Roche Recent Development Table 110. Eli Lilly Company Information Table 111. Eli Lilly Business Overview Table 112. Eli Lilly Malignant Mesothelioma Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 113. Eli Lilly Malignant Mesothelioma Drugs Product Portfolio Table 114. Eli Lilly Recent Development Table 115. Pfizer Company Information Table 116. Pfizer Business Overview Table 117. Pfizer Malignant Mesothelioma Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 118. Pfizer Malignant Mesothelioma Drugs Product Portfolio Table 119. Pfizer Recent Development Table 120. Fresenius Kabi Company Information Table 121. Fresenius Kabi Business Overview Table 122. Fresenius Kabi Malignant Mesothelioma Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 123. Fresenius Kabi Malignant Mesothelioma Drugs Product Portfolio Table 124. Fresenius Kabi Recent Development Table 125. AstraZeneca Company Information Table 126. AstraZeneca Business Overview Table 127. AstraZeneca Malignant Mesothelioma Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 128. AstraZeneca Malignant Mesothelioma Drugs Product Portfolio Table 129. AstraZeneca Recent Development Table 130. Polaris Pharmaceuticals Company Information Table 131. Polaris Pharmaceuticals Business Overview Table 132. Polaris Pharmaceuticals Malignant Mesothelioma Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 133. Polaris Pharmaceuticals Malignant Mesothelioma Drugs Product Portfolio Table 134. Polaris Pharmaceuticals Recent Development Table 135. Ono Pharmaceutical Company Information Table 136. Ono Pharmaceutical Business Overview Table 137. Ono Pharmaceutical Malignant Mesothelioma Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 138. Ono Pharmaceutical Malignant Mesothelioma Drugs Product Portfolio Table 139. Ono Pharmaceutical Recent Development Table 140. Nichi-Iko Pharmaceutical Company Information Table 141. Nichi-Iko Pharmaceutical Business Overview Table 142. Nichi-Iko Pharmaceutical Malignant Mesothelioma Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 143. Nichi-Iko Pharmaceutical Malignant Mesothelioma Drugs Product Portfolio Table 144. Nichi-Iko Pharmaceutical Recent Development Table 145. MolMed Company Information Table 146. MolMed Business Overview Table 147. MolMed Malignant Mesothelioma Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 148. MolMed Malignant Mesothelioma Drugs Product Portfolio Table 149. MolMed Recent Development Table 150. Kyowa Hakko Kirin Company Information Table 151. Kyowa Hakko Kirin Business Overview Table 152. Kyowa Hakko Kirin Malignant Mesothelioma Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 153. Kyowa Hakko Kirin Malignant Mesothelioma Drugs Product Portfolio Table 154. Kyowa Hakko Kirin Recent Development Table 155. Corden Pharma Company Information Table 156. Corden Pharma Business Overview Table 157. Corden Pharma Malignant Mesothelioma Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 158. Corden Pharma Malignant Mesothelioma Drugs Product Portfolio Table 159. Corden Pharma Recent Development Table 160. Concordia International Company Information Table 161. Concordia International Business Overview Table 162. Concordia International Malignant Mesothelioma Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 163. Concordia International Malignant Mesothelioma Drugs Product Portfolio Table 164. Concordia International Recent Development Table 165. Bristol-Myers Squibb Company Information Table 166. Bristol-Myers Squibb Business Overview Table 167. Bristol-Myers Squibb Malignant Mesothelioma Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 168. Bristol-Myers Squibb Malignant Mesothelioma Drugs Product Portfolio Table 169. Bristol-Myers Squibb Recent Development Table 170. Boehringer Ingelheim GmbH Company Information Table 171. Boehringer Ingelheim GmbH Business Overview Table 172. Boehringer Ingelheim GmbH Malignant Mesothelioma Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 173. Boehringer Ingelheim GmbH Malignant Mesothelioma Drugs Product Portfolio Table 174. Boehringer Ingelheim GmbH Recent Development Table 175. North America Malignant Mesothelioma Drugs Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 176. North America Malignant Mesothelioma Drugs Sales by Country (2021-2026) & (K Units) Table 177. North America Malignant Mesothelioma Drugs Sales Market Share by Country (2021-2026) Table 178. North America Malignant Mesothelioma Drugs Sales Forecast by Country (2027-2032) & (K Units) Table 179. North America Malignant Mesothelioma Drugs Sales Market Share Forecast by Country (2027-2032) Table 180. North America Malignant Mesothelioma Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 181. North America Malignant Mesothelioma Drugs Market Size by Country (2021-2026) & (US$ Million) Table 182. North America Malignant Mesothelioma Drugs Market Share by Country (2021-2026) Table 183. North America Malignant Mesothelioma Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 184. North America Malignant Mesothelioma Drugs Market Share Forecast by Country (2027-2032) Table 185. Europe Malignant Mesothelioma Drugs Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 186. Europe Malignant Mesothelioma Drugs Sales by Country (2021-2026) & (K Units) Table 187. Europe Malignant Mesothelioma Drugs Sales Market Share by Country (2021-2026) Table 188. Europe Malignant Mesothelioma Drugs Sales Forecast by Country (2027-2032) & (K Units) Table 189. Europe Malignant Mesothelioma Drugs Sales Market Share Forecast by Country (2027-2032) Table 190. Europe Malignant Mesothelioma Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 191. Europe Malignant Mesothelioma Drugs Market Size by Country (2021-2026) & (US$ Million) Table 192. Europe Malignant Mesothelioma Drugs Market Share by Country (2021-2026) Table 193. Europe Malignant Mesothelioma Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 194. Europe Malignant Mesothelioma Drugs Market Share Forecast by Country (2027-2032) Table 195. Asia-Pacific Malignant Mesothelioma Drugs Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 196. Asia-Pacific Malignant Mesothelioma Drugs Sales by Country (2021-2026) & (K Units) Table 197. Asia-Pacific Malignant Mesothelioma Drugs Sales Market Share by Country (2021-2026) Table 198. Asia-Pacific Malignant Mesothelioma Drugs Sales Forecast by Country (2027-2032) & (K Units) Table 199. Asia-Pacific Malignant Mesothelioma Drugs Sales Market Share Forecast by Country (2027-2032) Table 200. Asia-Pacific Malignant Mesothelioma Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 201. Asia-Pacific Malignant Mesothelioma Drugs Market Size by Country (2021-2026) & (US$ Million) Table 202. Asia-Pacific Malignant Mesothelioma Drugs Market Share by Country (2021-2026) Table 203. Asia-Pacific Malignant Mesothelioma Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 204. Asia-Pacific Malignant Mesothelioma Drugs Market Share Forecast by Country (2027-2032) Table 205. Latin America Malignant Mesothelioma Drugs Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 206. Latin America Malignant Mesothelioma Drugs Sales by Country (2021-2026) & (K Units) Table 207. Latin America Malignant Mesothelioma Drugs Sales Market Share by Country (2021-2026) Table 208. Latin America Malignant Mesothelioma Drugs Sales Forecast by Country (2027-2032) & (K Units) Table 209. Latin America Malignant Mesothelioma Drugs Sales Market Share Forecast by Country (2027-2032) Table 210. Latin America Malignant Mesothelioma Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 211. Latin America Malignant Mesothelioma Drugs Market Size by Country (2021-2026) & (US$ Million) Table 212. Latin America Malignant Mesothelioma Drugs Market Share by Country (2021-2026) Table 213. Latin America Malignant Mesothelioma Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 214. Latin America Malignant Mesothelioma Drugs Market Share Forecast by Country (2027-2032) Table 215. Middle East and Africa Malignant Mesothelioma Drugs Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 216. Middle East and Africa Malignant Mesothelioma Drugs Sales by Country (2021-2026) & (K Units) Table 217. Middle East and Africa Malignant Mesothelioma Drugs Sales Market Share by Country (2021-2026) Table 218. Middle East and Africa Malignant Mesothelioma Drugs Sales Forecast by Country (2027-2032) & (K Units) Table 219. Middle East and Africa Malignant Mesothelioma Drugs Sales Market Share Forecast by Country (2027-2032) Table 220. Middle East and Africa Malignant Mesothelioma Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 221. Middle East and Africa Malignant Mesothelioma Drugs Market Size by Country (2021-2026) & (US$ Million) Table 222. Middle East and Africa Malignant Mesothelioma Drugs Market Share by Country (2021-2026) Table 223. Middle East and Africa Malignant Mesothelioma Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 224. Middle East and Africa Malignant Mesothelioma Drugs Market Share Forecast by Country (2027-2032) Table 225. Key Raw Materials Table 226. Raw Materials Key Suppliers Table 227. Malignant Mesothelioma Drugs Distributors List Table 228. Malignant Mesothelioma Drugs Customers List Table 229. Research Programs/Design for This Report Table 230. Authors List of This Report Table 231. Secondary Sources Table 232. Primary Sources List of Figures Figure 1. Malignant Mesothelioma Drugs Image Figure 2. Global Malignant Mesothelioma Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Malignant Mesothelioma Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Malignant Mesothelioma Drugs Sales (2021-2032) & (K Units) Figure 5. Vinorelbine Image Figure 6. Global Vinorelbine Sales YoY Growth (2021-2032) & (K Units) Figure 7. Cisplatin Image Figure 8. Global Cisplatin Sales YoY Growth (2021-2032) & (K Units) Figure 9. Pemetrexed Image Figure 10. Global Pemetrexed Sales YoY Growth (2021-2032) & (K Units) Figure 11. Carboplatin Image Figure 12. Global Carboplatin Sales YoY Growth (2021-2032) & (K Units) Figure 13. Gemcitabine Image Figure 14. Global Gemcitabine Sales YoY Growth (2021-2032) & (K Units) Figure 15. Others Image Figure 16. Global Others Sales YoY Growth (2021-2032) & (K Units) Figure 17. Global Malignant Mesothelioma Drugs Market Size Overview by Type (2021-2032) & (US$ Million) Figure 18. Global Malignant Mesothelioma Drugs Market Share by Type 2025 VS 2032 Figure 19. North America Malignant Mesothelioma Drugs Sales Market Share in Volume by Type in 2025 Figure 20. North America Malignant Mesothelioma Drugs Sales Market Share in Value by Type in 2025 Figure 21. Europe Malignant Mesothelioma Drugs Sales Market Share in Volume by Type in 2025 Figure 22. Europe Malignant Mesothelioma Drugs Sales Market Share in Value by Type in 2025 Figure 23. Asia-Pacific Malignant Mesothelioma Drugs Sales Market Share in Volume by Type in 2025 Figure 24. Asia-Pacific Malignant Mesothelioma Drugs Sales Market Share in Value by Type in 2025 Figure 25. Latin America Malignant Mesothelioma Drugs Sales Market Share in Volume by Type in 2025 Figure 26. Latin America Malignant Mesothelioma Drugs Sales Market Share in Value by Type in 2025 Figure 27. Middle East and Africa Malignant Mesothelioma Drugs Sales Market Share in Volume by Type in 2025 Figure 28. Middle East and Africa Malignant Mesothelioma Drugs Sales Market Share in Value by Type in 2025 Figure 29. Global Top 5 and 10 Malignant Mesothelioma Drugs Players Market Share by Revenue in 2025 Figure 30. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 31. Retail Pharmacies Image Figure 32. Global Retail Pharmacies Sales YoY Growth (2021-2032) & (K Units) Figure 33. Hospital Pharmacies Image Figure 34. Global Hospital Pharmacies Sales YoY Growth (2021-2032) & (K Units) Figure 35. Oncology Centers Image Figure 36. Global Oncology Centers Sales YoY Growth (2021-2032) & (K Units) Figure 37. Others Image Figure 38. Global Others Sales YoY Growth (2021-2032) & (K Units) Figure 39. Global Malignant Mesothelioma Drugs Market Size Overview by Application (2021-2032) & (US$ Million) Figure 40. Global Malignant Mesothelioma Drugs Market Share by Application 2025 VS 2032 Figure 41. North America Malignant Mesothelioma Drugs Sales Market Share in Volume by Application in 2025 Figure 42. North America Malignant Mesothelioma Drugs Sales Market Share in Value by Application in 2025 Figure 43. Europe Malignant Mesothelioma Drugs Sales Market Share in Volume by Application in 2025 Figure 44. Europe Malignant Mesothelioma Drugs Sales Market Share in Value by Application in 2025 Figure 45. Asia-Pacific Malignant Mesothelioma Drugs Sales Market Share in Volume by Application in 2025 Figure 46. Asia-Pacific Malignant Mesothelioma Drugs Sales Market Share in Value by Application in 2025 Figure 47. Latin America Malignant Mesothelioma Drugs Sales Market Share in Volume by Application in 2025 Figure 48. Latin America Malignant Mesothelioma Drugs Sales Market Share in Value by Application in 2025 Figure 49. Middle East and Africa Malignant Mesothelioma Drugs Sales Market Share in Volume by Application in 2025 Figure 50. Middle East and Africa Malignant Mesothelioma Drugs Sales Market Share in Value by Application in 2025 Figure 51. North America Malignant Mesothelioma Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 52. North America Malignant Mesothelioma Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 53. North America Malignant Mesothelioma Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 54. North America Malignant Mesothelioma Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 55. Europe Malignant Mesothelioma Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 56. Europe Malignant Mesothelioma Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 57. Europe Malignant Mesothelioma Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Europe Malignant Mesothelioma Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 59. Asia-Pacific Malignant Mesothelioma Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 60. Asia-Pacific Malignant Mesothelioma Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 61. Asia-Pacific Malignant Mesothelioma Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 62. Asia-Pacific Malignant Mesothelioma Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 63. Latin America Malignant Mesothelioma Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 64. Latin America Malignant Mesothelioma Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 65. Latin America Malignant Mesothelioma Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 66. Latin America Malignant Mesothelioma Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 67. Middle East and Africa Malignant Mesothelioma Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 68. Middle East and Africa Malignant Mesothelioma Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 69. Middle East and Africa Malignant Mesothelioma Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 70. Middle East and Africa Malignant Mesothelioma Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 71. Malignant Mesothelioma Drugs Value Chain Figure 72. Key Raw Materials Price Figure 73. Manufacturing Cost Structure Figure 74. Malignant Mesothelioma Drugs Production Mode & Process Figure 75. Direct Comparison with Distribution Share Figure 76. Distributors Profiles Figure 77. Years Considered Figure 78. Research Process Figure 79. Key Executives Interviewed

Scope & coverage.

Types
  • Vinorelbine
  • Cisplatin
  • Pemetrexed
  • Carboplatin
  • Gemcitabine
  • Others
Applications
  • Retail Pharmacies
  • Hospital Pharmacies
  • Oncology Centers
  • Others
Companies covered
  • Teva Pharmaceuticals
  • Sun Pharmaceuticals
  • Sanofi
  • Novartis
  • Merck
  • Mylan
  • Roche
  • Eli Lilly
  • Pfizer
  • Fresenius Kabi
  • AstraZeneca
  • Polaris Pharmaceuticals
  • Ono Pharmaceutical
  • Nichi-Iko Pharmaceutical
  • MolMed
  • Kyowa Hakko Kirin
  • Corden Pharma
  • Concordia International
  • Bristol-Myers Squibb
  • Boehringer Ingelheim GmbH

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Malignant Mesothelioma Drugs Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Malignant Mesothelioma Drugs Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Malignant Mesothelioma Drugs Market by Type
  6. 1.3.1 Vinorelbine
  7. 1.3.2 Cisplatin
  8. 1.3.3 Pemetrexed
  9. 1.3.4 Carboplatin
  10. 1.3.5 Gemcitabine
  11. 1.3.6 Others
  12. 1.4 Global Malignant Mesothelioma Drugs Market Size by Type
  13. 1.4.1 Global Malignant Mesothelioma Drugs Market Size Overview by Type (2021-2032)
  14. 1.4.2 Global Malignant Mesothelioma Drugs Historic Market Size Review by Type (2021-2026)
  15. 1.4.3 Global Malignant Mesothelioma Drugs Forecasted Market Size by Type (2027-2032)
  16. 1.5 Key Regions Market Size by Type
  17. 1.5.1 North America Malignant Mesothelioma Drugs Sales Breakdown by Type (2021-2026)
  18. 1.5.2 Europe Malignant Mesothelioma Drugs Sales Breakdown by Type (2021-2026)
  19. 1.5.3 Asia-Pacific Malignant Mesothelioma Drugs Sales Breakdown by Type (2021-2026)
  20. 1.5.4 South America Malignant Mesothelioma Drugs Sales Breakdown by Type (2021-2026)
  21. 1.5.5 Middle East and Africa Malignant Mesothelioma Drugs Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Malignant Mesothelioma Drugs Industry Trends
  2. 2.2 Malignant Mesothelioma Drugs Industry Drivers
  3. 2.3 Malignant Mesothelioma Drugs Industry Opportunities and Challenges
  4. 2.4 Malignant Mesothelioma Drugs Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Malignant Mesothelioma Drugs Revenue (2021-2026)
  2. 3.2 Global Top Players by Malignant Mesothelioma Drugs Sales (2021-2026)
  3. 3.3 Global Top Players by Malignant Mesothelioma Drugs Price (2021-2026)
  4. 3.4 Global Malignant Mesothelioma Drugs Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Malignant Mesothelioma Drugs Major Company Production Sites & Headquarters
  6. 3.6 Global Malignant Mesothelioma Drugs Company, Product Type & Application
  7. 3.7 Global Malignant Mesothelioma Drugs Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Malignant Mesothelioma Drugs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Malignant Mesothelioma Drugs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Malignant Mesothelioma Drugs Tier 1, Tier 2, and Tier 3
4 Malignant Mesothelioma Drugs Regional Status and Outlook
  1. 4.1 Global Malignant Mesothelioma Drugs Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Malignant Mesothelioma Drugs Historic Market Size by Region
  3. 4.2.1 Global Malignant Mesothelioma Drugs Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Malignant Mesothelioma Drugs Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Malignant Mesothelioma Drugs Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Malignant Mesothelioma Drugs Forecasted Market Size by Region
  7. 4.3.1 Global Malignant Mesothelioma Drugs Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Malignant Mesothelioma Drugs Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Malignant Mesothelioma Drugs Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Malignant Mesothelioma Drugs by Application
  1. 5.1 Malignant Mesothelioma Drugs Market by Application
  2. 5.1.1 Retail Pharmacies
  3. 5.1.2 Hospital Pharmacies
  4. 5.1.3 Oncology Centers
  5. 5.1.4 Others
  6. 5.2 Global Malignant Mesothelioma Drugs Market Size by Application
  7. 5.2.1 Global Malignant Mesothelioma Drugs Market Size Overview by Application (2021-2032)
  8. 5.2.2 Global Malignant Mesothelioma Drugs Historic Market Size Review by Application (2021-2026)
  9. 5.2.3 Global Malignant Mesothelioma Drugs Forecasted Market Size by Application (2027-2032)
  10. 5.3 Key Regions Market Size by Application
  11. 5.3.1 North America Malignant Mesothelioma Drugs Sales Breakdown by Application (2021-2026)
  12. 5.3.2 Europe Malignant Mesothelioma Drugs Sales Breakdown by Application (2021-2026)
  13. 5.3.3 Asia-Pacific Malignant Mesothelioma Drugs Sales Breakdown by Application (2021-2026)
  14. 5.3.4 South America Malignant Mesothelioma Drugs Sales Breakdown by Application (2021-2026)
  15. 5.3.5 Middle East and Africa Malignant Mesothelioma Drugs Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Teva Pharmaceuticals
  2. 6.1.1 Teva Pharmaceuticals Company Information
  3. 6.1.2 Teva Pharmaceuticals Business Overview
  4. 6.1.3 Teva Pharmaceuticals Malignant Mesothelioma Drugs Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Teva Pharmaceuticals Malignant Mesothelioma Drugs Product Portfolio
  6. 6.1.5 Teva Pharmaceuticals Recent Developments
  7. 6.2 Sun Pharmaceuticals
  8. 6.2.1 Sun Pharmaceuticals Company Information
  9. 6.2.2 Sun Pharmaceuticals Business Overview
  10. 6.2.3 Sun Pharmaceuticals Malignant Mesothelioma Drugs Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Sun Pharmaceuticals Malignant Mesothelioma Drugs Product Portfolio
  12. 6.2.5 Sun Pharmaceuticals Recent Developments
  13. 6.3 Sanofi
  14. 6.3.1 Sanofi Company Information
  15. 6.3.2 Sanofi Business Overview
  16. 6.3.3 Sanofi Malignant Mesothelioma Drugs Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Sanofi Malignant Mesothelioma Drugs Product Portfolio
  18. 6.3.5 Sanofi Recent Developments
  19. 6.4 Novartis
  20. 6.4.1 Novartis Company Information
  21. 6.4.2 Novartis Business Overview
  22. 6.4.3 Novartis Malignant Mesothelioma Drugs Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Novartis Malignant Mesothelioma Drugs Product Portfolio
  24. 6.4.5 Novartis Recent Developments
  25. 6.5 Merck
  26. 6.5.1 Merck Company Information
  27. 6.5.2 Merck Business Overview
  28. 6.5.3 Merck Malignant Mesothelioma Drugs Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Merck Malignant Mesothelioma Drugs Product Portfolio
  30. 6.5.5 Merck Recent Developments
  31. 6.6 Mylan
  32. 6.6.1 Mylan Company Information
  33. 6.6.2 Mylan Business Overview
  34. 6.6.3 Mylan Malignant Mesothelioma Drugs Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Mylan Malignant Mesothelioma Drugs Product Portfolio
  36. 6.6.5 Mylan Recent Developments
  37. 6.7 Roche
  38. 6.7.1 Roche Company Information
  39. 6.7.2 Roche Business Overview
  40. 6.7.3 Roche Malignant Mesothelioma Drugs Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Roche Malignant Mesothelioma Drugs Product Portfolio
  42. 6.7.5 Roche Recent Developments
  43. 6.8 Eli Lilly
  44. 6.8.1 Eli Lilly Company Information
  45. 6.8.2 Eli Lilly Business Overview
  46. 6.8.3 Eli Lilly Malignant Mesothelioma Drugs Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Eli Lilly Malignant Mesothelioma Drugs Product Portfolio
  48. 6.8.5 Eli Lilly Recent Developments
  49. 6.9 Pfizer
  50. 6.9.1 Pfizer Company Information
  51. 6.9.2 Pfizer Business Overview
  52. 6.9.3 Pfizer Malignant Mesothelioma Drugs Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Pfizer Malignant Mesothelioma Drugs Product Portfolio
  54. 6.9.5 Pfizer Recent Developments
  55. 6.10 Fresenius Kabi
  56. 6.10.1 Fresenius Kabi Company Information
  57. 6.10.2 Fresenius Kabi Business Overview
  58. 6.10.3 Fresenius Kabi Malignant Mesothelioma Drugs Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 Fresenius Kabi Malignant Mesothelioma Drugs Product Portfolio
  60. 6.10.5 Fresenius Kabi Recent Developments
  61. 6.11 AstraZeneca
  62. 6.11.1 AstraZeneca Company Information
  63. 6.11.2 AstraZeneca Business Overview
  64. 6.11.3 AstraZeneca Malignant Mesothelioma Drugs Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 AstraZeneca Malignant Mesothelioma Drugs Product Portfolio
  66. 6.11.5 AstraZeneca Recent Developments
  67. 6.12 Polaris Pharmaceuticals
  68. 6.12.1 Polaris Pharmaceuticals Company Information
  69. 6.12.2 Polaris Pharmaceuticals Business Overview
  70. 6.12.3 Polaris Pharmaceuticals Malignant Mesothelioma Drugs Sales, Revenue and Gross Margin (2021-2026)
  71. 6.12.4 Polaris Pharmaceuticals Malignant Mesothelioma Drugs Product Portfolio
  72. 6.12.5 Polaris Pharmaceuticals Recent Developments
  73. 6.13 Ono Pharmaceutical
  74. 6.13.1 Ono Pharmaceutical Company Information
  75. 6.13.2 Ono Pharmaceutical Business Overview
  76. 6.13.3 Ono Pharmaceutical Malignant Mesothelioma Drugs Sales, Revenue and Gross Margin (2021-2026)
  77. 6.13.4 Ono Pharmaceutical Malignant Mesothelioma Drugs Product Portfolio
  78. 6.13.5 Ono Pharmaceutical Recent Developments
  79. 6.14 Nichi-Iko Pharmaceutical
  80. 6.14.1 Nichi-Iko Pharmaceutical Company Information
  81. 6.14.2 Nichi-Iko Pharmaceutical Business Overview
  82. 6.14.3 Nichi-Iko Pharmaceutical Malignant Mesothelioma Drugs Sales, Revenue and Gross Margin (2021-2026)
  83. 6.14.4 Nichi-Iko Pharmaceutical Malignant Mesothelioma Drugs Product Portfolio
  84. 6.14.5 Nichi-Iko Pharmaceutical Recent Developments
  85. 6.15 MolMed
  86. 6.15.1 MolMed Company Information
  87. 6.15.2 MolMed Business Overview
  88. 6.15.3 MolMed Malignant Mesothelioma Drugs Sales, Revenue and Gross Margin (2021-2026)
  89. 6.15.4 MolMed Malignant Mesothelioma Drugs Product Portfolio
  90. 6.15.5 MolMed Recent Developments
  91. 6.16 Kyowa Hakko Kirin
  92. 6.16.1 Kyowa Hakko Kirin Company Information
  93. 6.16.2 Kyowa Hakko Kirin Business Overview
  94. 6.16.3 Kyowa Hakko Kirin Malignant Mesothelioma Drugs Sales, Revenue and Gross Margin (2021-2026)
  95. 6.16.4 Kyowa Hakko Kirin Malignant Mesothelioma Drugs Product Portfolio
  96. 6.16.5 Kyowa Hakko Kirin Recent Developments
  97. 6.17 Corden Pharma
  98. 6.17.1 Corden Pharma Company Information
  99. 6.17.2 Corden Pharma Business Overview
  100. 6.17.3 Corden Pharma Malignant Mesothelioma Drugs Sales, Revenue and Gross Margin (2021-2026)
  101. 6.17.4 Corden Pharma Malignant Mesothelioma Drugs Product Portfolio
  102. 6.17.5 Corden Pharma Recent Developments
  103. 6.18 Concordia International
  104. 6.18.1 Concordia International Company Information
  105. 6.18.2 Concordia International Business Overview
  106. 6.18.3 Concordia International Malignant Mesothelioma Drugs Sales, Revenue and Gross Margin (2021-2026)
  107. 6.18.4 Concordia International Malignant Mesothelioma Drugs Product Portfolio
  108. 6.18.5 Concordia International Recent Developments
  109. 6.19 Bristol-Myers Squibb
  110. 6.19.1 Bristol-Myers Squibb Company Information
  111. 6.19.2 Bristol-Myers Squibb Business Overview
  112. 6.19.3 Bristol-Myers Squibb Malignant Mesothelioma Drugs Sales, Revenue and Gross Margin (2021-2026)
  113. 6.19.4 Bristol-Myers Squibb Malignant Mesothelioma Drugs Product Portfolio
  114. 6.19.5 Bristol-Myers Squibb Recent Developments
  115. 6.20 Boehringer Ingelheim GmbH
  116. 6.20.1 Boehringer Ingelheim GmbH Company Information
  117. 6.20.2 Boehringer Ingelheim GmbH Business Overview
  118. 6.20.3 Boehringer Ingelheim GmbH Malignant Mesothelioma Drugs Sales, Revenue and Gross Margin (2021-2026)
  119. 6.20.4 Boehringer Ingelheim GmbH Malignant Mesothelioma Drugs Product Portfolio
  120. 6.20.5 Boehringer Ingelheim GmbH Recent Developments
7 North America by Country
  1. 7.1 North America Malignant Mesothelioma Drugs Sales by Country
  2. 7.1.1 North America Malignant Mesothelioma Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Malignant Mesothelioma Drugs Sales by Country (2021-2026)
  4. 7.1.3 North America Malignant Mesothelioma Drugs Sales Forecast by Country (2027-2032)
  5. 7.2 North America Malignant Mesothelioma Drugs Market Size by Country
  6. 7.2.1 North America Malignant Mesothelioma Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Malignant Mesothelioma Drugs Market Size by Country (2021-2026)
  8. 7.2.3 North America Malignant Mesothelioma Drugs Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Malignant Mesothelioma Drugs Sales by Country
  2. 8.1.1 Europe Malignant Mesothelioma Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Malignant Mesothelioma Drugs Sales by Country (2021-2026)
  4. 8.1.3 Europe Malignant Mesothelioma Drugs Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Malignant Mesothelioma Drugs Market Size by Country
  6. 8.2.1 Europe Malignant Mesothelioma Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Malignant Mesothelioma Drugs Market Size by Country (2021-2026)
  8. 8.2.3 Europe Malignant Mesothelioma Drugs Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Malignant Mesothelioma Drugs Sales by Country
  2. 9.1.1 Asia-Pacific Malignant Mesothelioma Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Malignant Mesothelioma Drugs Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Malignant Mesothelioma Drugs Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Malignant Mesothelioma Drugs Market Size by Country
  6. 9.2.1 Asia-Pacific Malignant Mesothelioma Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Malignant Mesothelioma Drugs Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Malignant Mesothelioma Drugs Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Malignant Mesothelioma Drugs Sales by Country
  2. 10.1.1 South America Malignant Mesothelioma Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Malignant Mesothelioma Drugs Sales by Country (2021-2026)
  4. 10.1.3 South America Malignant Mesothelioma Drugs Sales Forecast by Country (2027-2032)
  5. 10.2 South America Malignant Mesothelioma Drugs Market Size by Country
  6. 10.2.1 South America Malignant Mesothelioma Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Malignant Mesothelioma Drugs Market Size by Country (2021-2026)
  8. 10.2.3 South America Malignant Mesothelioma Drugs Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Malignant Mesothelioma Drugs Sales by Country
  2. 11.1.1 Middle East and Africa Malignant Mesothelioma Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Malignant Mesothelioma Drugs Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Malignant Mesothelioma Drugs Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Malignant Mesothelioma Drugs Market Size by Country
  6. 11.2.1 Middle East and Africa Malignant Mesothelioma Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Malignant Mesothelioma Drugs Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Malignant Mesothelioma Drugs Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Malignant Mesothelioma Drugs Value Chain Analysis
  2. 12.1.1 Malignant Mesothelioma Drugs Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Malignant Mesothelioma Drugs Production Mode & Process
  7. 12.2 Malignant Mesothelioma Drugs Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Malignant Mesothelioma Drugs Distributors
  10. 12.2.3 Malignant Mesothelioma Drugs Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst